leadf
logo-loader
RNS
viewAvacta Group PLC

Avacta Group PLC - Turner Pope Investor Evening

RNS Number : 6749C
Avacta Group PLC
19 June 2019
 

 

19 June 2019

 Avacta Group plc

("Avacta", the "Company" or the "Group")

 

Turner Pope Investor Evening

 

Avacta Group plc (AIM: AVCT.L), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that the Group's Chief Executive, Alastair Smith, will be presenting at an investor evening hosted by Turner Pope Investments on Wednesday, 3 July 2019. The event will be held in London, EC2 and commence at 4pm.

 

To register your interest, please email info@turnerpope.com or call on 0203 621 4124.

 

- Ends -

 

 

 

For further information from Avacta Group plc, please contact:

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

 

Tel:  +44 (0) 844 414 0452

www.avacta.com

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Giles Rolls - Corporate Finance

Tim Redfern - ECM

 

WG Partners (Joint Broker)

Nigel Birks / Nigel Barnes

David Wilson / Claes Spang

 

Tel:  +44 (0) 207 220 0500

www.finncap.com

 

 

Tel:  +44 (0) 203 705 9318

Tel:  +44 (0) 203 705 9217

www.wgpartners.co.uk

 

Turner Pope Investments

James Pope / Ben Turner

 

Yellow Jersey PR (Financial Media and IR)

Sarah Hollins

Harriet Jackson

 

Zyme Communications (Trade and Regional Media)

Katie Odgaard

Tel: +44 (0) 203 621 4120

www.turnerpope.com

 

 

Tel: +44 (0)7764 947 137

Tel: +44 (0)7544 275 882

avacta@yellowjerseypr.com

 

Tel: +44 (0)7787 502 947

katie.odgaard@zymecommunications.com 

 

About Avacta Group plc - https://www.avacta.com

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

 

Antibodies dominate markets worth in excess of $100bn despite their shortcomings.  Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability.  Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

 

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes.  Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics. 

 

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRALLFFRRIITLIA

Quick facts: Avacta Group PLC

Price: 166

Market: AIM
Market Cap: £416.08 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Avacta Plc's therapeutics business 'has huge amount of potential' - analyst...

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space. The group's reported interim results to January 2019 today, revealing revenues of...

on 9/4/19